🕵️ DAY One Biopharmaceuticals, Inc. ($DAWN)
SEC insider & ownership activity, last 12 months · CIK 1845337 · every row links its SEC filing
Over the last 12 months insiders sold $864K with no open-market buying against it. Jeremy Bender sold $430K in discretionary trades (Aug–Feb). Blackrock, Inc. added 4.7% → 5.8%. One red-flag 8-K in the window: Delisting notice (3.01), Apr 22, 2026.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
0 buyers, $0 (0 lots) · 5 sellers, $864K (13 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Jeremy Bender | 0 | – | 3 | $430K | Feb 17, 2026 |
| Adam Dubow | 0 | – | 3 | $142K | Feb 17, 2026 |
| Charles York | 0 | – | 3 | $134K | Feb 17, 2026 |
| Lauren Merendino | 0 | – | 3 | $126K | Feb 17, 2026 |
| Vasconcelles Michael | 0 | – | 1 | $32K | Feb 17, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Blackrock, Inc. | 5.8% | 13G | Jul 17, 2025 | filing ↗ | |
| Glazer Capital, LLC | 5.4% | 13G | Mar 19, 2026 | filing ↗ | |
| Paul J. Glazer | 5.4% | 13G | Mar 19, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Jeremy Bender | $179K | Feb 17, 2026 | filing ↗ |
| Charles York | $70K | Feb 17, 2026 | filing ↗ |
| Lauren Merendino | $67K | Feb 17, 2026 | filing ↗ |
| Adam Dubow | $74K | Feb 17, 2026 | filing ↗ |
| Charles York | $36K | Nov 17, 2025 | filing ↗ |
| Lauren Merendino | $33K | Nov 17, 2025 | filing ↗ |
| Adam Dubow | $39K | Nov 17, 2025 | filing ↗ |
| Jeremy Bender | $142K | Nov 17, 2025 | filing ↗ |
| Jeremy Bender | $109K | Aug 18, 2025 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Agreement terminated (1.02) | Apr 22, 2026 | filing ↗ |
| Acquisition or disposition (2.01) | Apr 22, 2026 | filing ↗ |
| Delisting notice (3.01) | Apr 22, 2026 | filing ↗ |
| Material Modifications to Rights of Security Holders (3.03) | Apr 22, 2026 | filing ↗ |
| Change of control (5.01) | Apr 22, 2026 | filing ↗ |
| Officer/director changes (5.02) | Apr 22, 2026 | filing ↗ |
| Charter/bylaw changes (5.03) | Apr 22, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 22, 2026 | filing ↗ |
| Material agreement (1.01) | Mar 6, 2026 | filing ↗ |
| Other events (8.01) | Mar 6, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 6, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Mar 2, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 2, 2026 | filing ↗ |
| Earnings (2.02) | Feb 24, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Feb 24, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 24, 2026 | filing ↗ |
| Earnings (2.02) | Jan 11, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 11, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 11, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 6, 2026 | filing ↗ |
| Material agreement (1.01) | Jan 6, 2026 | filing ↗ |
| Acquisition or disposition (2.01) | Jan 6, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 6, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 6, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Nov 24, 2025 | filing ↗ |
| Other events (8.01) | Nov 24, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 24, 2025 | filing ↗ |
| Material agreement (1.01) | Nov 12, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Nov 12, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 12, 2025 | filing ↗ |